Shares of Verastem, Inc. (NASDAQ:VSTM) traded up 1.1% during trading on Thursday . The stock traded as high as $5.55 and last traded at $4.98. 2,933,055 shares changed hands during trading, an increase of 127% from the average session volume of 1,293,490 shares. The stock had previously closed at $4.92.

Several analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target (up from $6.50) on shares of Verastem in a research report on Thursday. Cann reiterated a “buy” rating on shares of Verastem in a research report on Wednesday, August 16th. ValuEngine cut Verastem from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut Verastem from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. Finally, Oppenheimer Holdings, Inc. set a $6.00 price target on Verastem and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $5.04.

The stock’s market capitalization is $182.74 million. The company has a 50 day moving average of $3.54 and a 200 day moving average of $2.45.

Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.02. On average, equities analysts predict that Verastem, Inc. will post ($1.38) EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. TFS Capital LLC acquired a new stake in shares of Verastem during the first quarter worth $113,000. Renaissance Technologies LLC boosted its holdings in shares of Verastem by 20.0% during the first quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock worth $2,539,000 after purchasing an additional 204,400 shares during the last quarter. Alpine Woods Capital Investors LLC acquired a new stake in shares of Verastem during the second quarter worth $109,000. Howland Capital Management LLC boosted its holdings in shares of Verastem by 16.5% during the second quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock worth $641,000 after purchasing an additional 41,616 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Verastem during the second quarter worth $234,000. Institutional investors and hedge funds own 24.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Verastem, Inc. (VSTM) Trading 1.1% Higher” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/07/verastem-inc-vstm-trading-1-1-higher.html.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.